NCT00424502View on ClinicalTrials.gov

A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a TNF-Blocker.

PHASE4CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

October 31, 2009

Study Completion Date

October 31, 2009

Conditions
Rheumatoid Arthritis
Interventions
DRUG

rituximab [MabThera/Rituxan]

1g iv on days 1 and 15

DRUG

Methotrexate

10-25mg po/week

Trial Locations (3)

1023

Budapest

1027

Budapest

4032

Debrecen

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT00424502 - A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a TNF-Blocker. | Biotech Hunter | Biotech Hunter